Article Text
Abstract
Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists.
These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.
- MYASTHENIA
Statistics from Altmetric.com
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Linked Articles
- Editors' commentary
Other content recommended for you
- Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis
- Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
- Update on myasthenia gravis
- Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment
- When the patient fails to respond to treatment: myasthenia gravis
- New and emerging treatments for myasthenia gravis
- Myasthenia gravis and other neuromuscular junction disorders
- Myasthenia and related disorders of the neuromuscular junction
- A case of diplopia and arm weakness
- THE NEUROMUSCULAR JUNCTION DISORDERS